American Society of Hematology

Figure 2.

Mutational signatures operating in PMBLs. (A) De novo discovery identified 4 mutational signatures in 37 PMBLs using SignatureAnalyzer63: spontaneous deamination at CpGs (C>T CpG, aging, COSMIC1), APOBEC (COSMIC2 and COSMIC13), AID, and MSI (COSMIC26). (B) Signature activity as total count of contributing mutations in 37 PMBCLs. Nearest mutation distance <10 kb. (C) Proportion of each signature for mutations in significantly mutated genes (MutSig2CVq < 0.1). This is based on the mean likelihood of association (supplemental Methods) of each mutation to each signature (left). Error bars reflect the standard error. Total number of mutations depicted as histogram (right).

Mutational signatures operating in PMBLs. (A) De novo discovery identified 4 mutational signatures in 37 PMBLs using SignatureAnalyzer⁶³: spontaneous deamination at CpGs (C>T CpG, aging, COSMIC1), APOBEC (COSMIC2 and COSMIC13), AID, and MSI (COSMIC26). (B) Signature activity as total count of contributing mutations in 37 PMBCLs. Nearest mutation distance <10 kb. (C) Proportion of each signature for mutations in significantly mutated genes (MutSig2CVq < 0.1). This is based on the mean likelihood of association (supplemental Methods) of each mutation to each signature (left). Error bars reflect the standard error. Total number of mutations depicted as histogram (right).

This Feature Is Available To Subscribers Only